United Therapeutics Corporation (UTHR)

Market Cap	16.17B
Revenue (ttm)	2.76B
Net Income (ttm)	1.11B
Shares Out	44.64M
EPS (ttm)	22.72
PE Ratio	15.95
Forward PE	12.50
Dividend	n/a
Ex-Dividend Date	n/a

Volume	37,022
Open	359.50
Previous Close	360.16
Day's Range	359.50 - 362.39
52-Week Range	208.62 - 417.82
Beta	0.55
Analysts	Buy
Price Target	370.86 (+2.4%)
Earnings Date	Feb 19, 2025

About UTHR

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 17, 1999
• Employees: 1,168
• Stock Exchange: NASDAQ
• Ticker Symbol: UTHR
• Website: https://www.unither.com

Financial Performance

In 2023, United Therapeutics's revenue was $2.33 billion, an increase of 20.20% compared to the previous year's $1.94 billion. Earnings were $984.80 million, an increase of 35.40%.

Analyst Forecast

According to 14 analysts, the average rating for UTHR stock is "Buy." The 12-month stock price forecast is $370.86, which is an increase of 2.40% from the latest price.

Price Target

$370.86

(2.40% upside)

Analyst Consensus: Buy